Evidence map›Paper›PMID 40059815›Full record

ArticleThe veterinary quarterly2025

Clinical evaluation of HuDo-CSPG4 DNA electroporation as adjuvant treatment for canine oral malignant melanoma: comparison of two vaccination protocols.

Mariateresa Camerino, Davide Giacobino, Lidia Tarone, Alfredo Dentini, Marina Martano, Emanuela Morello, Erica Ilaria Ferraris, Luca Manassero, Selina Iussich, Lorella Maniscalco and 3 more

Abstract readComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The veterinary quarterly, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mariateresa CamerinoAniCura Animal Oncology and Imaging Center, Hünenberg, Switzerland.ORCID 0009-0002-8291-0333
Davide GiacobinoDepartment of Veterinary Sciences, University of Turin, Turin, Italy.ORCID 0000-0001-8906-9490
Lidia TaroneDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Turin, Turin, Italy.ORCID 0000-0003-2376-636X
Alfredo DentiniAniCura Clinica Veterinaria Tyrus, Terni, Italy.
Marina MartanoDepartment of Veterinary Sciences, University of Parma, Parma, Italy.ORCID 0000-0002-2159-0930
Emanuela MorelloDepartment of Veterinary Sciences, University of Turin, Turin, Italy.ORCID 0000-0002-9801-6646
Erica Ilaria FerrarisDepartment of Veterinary Sciences, University of Turin, Turin, Italy.ORCID 0000-0002-7164-0617
Luca ManasseroDepartment of Veterinary Sciences, University of Turin, Turin, Italy.
Selina IussichDepartment of Veterinary Sciences, University of Turin, Turin, Italy.ORCID 0000-0003-0361-131X
Lorella ManiscalcoDepartment of Veterinary Sciences, University of Turin, Turin, Italy.ORCID 0000-0001-5504-7218
Federica CavalloDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Turin, Turin, Italy.ORCID 0000-0003-4571-1060
Federica RiccardoDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Turin, Turin, Italy.ORCID 0000-0002-9692-0172
Paolo BuraccoDepartment of Veterinary Sciences, University of Turin, Turin, Italy.ORCID 0000-0002-0181-0887

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Canine oral malignant melanoma (OMM) is an aggressive, spontaneously occurring tumor carrying a poor to guarded prognosis and relatively limited therapeutic strategies. In this landscape, chondroitin sulfate proteoglycan (CSPG)4 represents a promising immunotherapeutic target. The objective of this bi-center prospective study was to examine the clinical outcome of OMM-bearing dogs treated with surgery and adjuvant electroporation using a DNA vaccine (HuDo-CSPG4) encoding both human (Hu) and canine (Do) portions of CSPG4 through two different vaccination protocols. Dogs with stage I-III surgically resected CSPG4-positive OMM underwent HuDo-CSPG4 plasmid electroporation starting at the 3

Indexed as

Cancer VaccinesChondroitin Sulfate ProteoglycansDog DiseasesMelanomaMouth NeoplasmsVaccines, DNAAnimalsDogsElectroporationFemaleMaleProspective StudiesVaccinationCancer VaccinesChondroitin Sulfate ProteoglycansVaccines, DNAadjuvant immunotherapyCanine oral malignant melanomaCSPG4DNA electroporationHuDo-CSPG4

Identifiers

PMID40059815
PMCPMC11894750

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.